Page last updated: 2024-11-01

nimodipine and Hallucinations

nimodipine has been researched along with Hallucinations in 1 studies

Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.

Hallucinations: Subjectively experienced sensations in the absence of an appropriate stimulus, but which are regarded by the individual as real. They may be of organic origin or associated with MENTAL DISORDERS.

Research Excerpts

ExcerptRelevanceReference
"Susac's syndrome is an extremely rare clinical manifestation characterized by the triad of fluctuating sensorineural hearing loss, sudden visual loss and encephalopathy."2.41[Susac syndrome as a cause of sensorineural hearing loss]. ( Albaladejo Devis, I; Cubillana Herrero, JD; Jiménez Cervantes-Nicolás, JA; Minguez Merlos, N; Rodríguez González-Herrero, B; Soler Valcárcel, A, 2002)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cubillana Herrero, JD1
Soler Valcárcel, A1
Albaladejo Devis, I1
Rodríguez González-Herrero, B1
Minguez Merlos, N1
Jiménez Cervantes-Nicolás, JA1

Reviews

1 review available for nimodipine and Hallucinations

ArticleYear
[Susac syndrome as a cause of sensorineural hearing loss].
    Acta otorrinolaringologica espanola, 2002, Volume: 53, Issue:5

    Topics: Adult; Anti-Inflammatory Agents; Aspirin; Cerebral Infarction; Cochlea; Combined Modality Therapy; D

2002